Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $3.92 Analyst target: $8.33 Upside: 112.50%
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for the treatment or prevention of addictions and related disorders. The company is headquartered in Charlottesville, Virginia.
See the full interactive analysis & chart →Informational only — not investment advice.